Lack of baby formula producers exacerbating the shortage
Ripple effects from plant closing have been widespread
In the early 1990s, the nation’s biggest makers of baby formula were under fire.
The three largest manufacturers, which controlled 90 percent of the U.S. market at the time, were hit with waves of state, federal and corporate lawsuits, accusing them of attempting to limit competition in the space and using their control of the industry to fix prices. Most of the lawsuits were settled or, in some cases, won by the companies.
Three decades later, the $2.1 billion industry is still controlled by a small number of manufacturers, which are again in the crosshairs over their outsized market share.
The infant formula market was plunged into disarray when Abbott Laboratories voluntarily recalled some of its most popular powdered formulas in February and shut down its plant in Sturgis, Michigan, after four babies who had consumed some of Abbott’s products became sick with bacterial infections.
Abbott, which controls 48 percent of the market, has said that there was no evidence its formula caused any known infant illnesses and that none of the tests performed by regulators have directly linked the cans of formula the babies consumed to the strains of bacteria, Cronobacter sakazakii, found at the plant.
But the ripple effects from that single plant closing have been widespread, highlighting the market power of a single manufacturer and the lack of meaningful competition in an industry governed by rules and regulations designed to protect the incumbents.
Stores are limiting purchases of baby formula, with shelves in many markets completely bare. Panicked parents of newborns are calling on friends and family to help locate food for their babies, with some resorting to making their own formula at home. And while the Abbott plant was given the green light this week to start manufacturing again — a move that will still take weeks to rebuild inventory on store shelves — there are growing calls from lawmakers for major changes to how the industry operates.
“When something goes wrong, like it has here, you then have a major, serious crisis,” said Rep. Rosa Delauro, D-conn., who released a scathing 34-page whistleblower report from a former Abbott employee detailing safety and cleanliness issues at the Sturgis plant. She argued that the industry should be broken up and efforts should be made to promote competition to avoid future shortages.
Sen. Tammy Duckworth, D-ill., urged the Federal Trade Commission last week to conduct a broad study of the infant formula industry and whether market consolidation has led to the dire shortages.
Top Biden administration officials have also lamented the power of a few players. On Sunday, Transportation Secretary Pete Buttigieg said the Biden administration should do more to address the industry’s “enormous market concentration.”
“We’ve got four companies making about 90 percent of the formula in this country, which we should probably take a look at,” Buttigieg said on
CBS’ “Face the Nation.”
Today, Abbott is the biggest player. Mead Johnson, which is owned by conglomerate Reckitt Benckiser, and Perrigo, which makes generic formula for retailers, control an additional 31 percent. Nestlé controls less than 8 percent.
In part, the lack of competition stems from simple math: Few companies or investors are eager to jump into the infant formula industry because its growth is tied to the nation’s birthrate, which held steady for decades until it began dropping in 2007.
But the factors that long ago led to the creation of an industry controlled by a handful of manufacturers are primarily rooted in a tangled web of trade rules and regulations that have protected the biggest producers and made it challenging for others to enter the market.
The United States, which produces 98 percent of formula consumed in the country, has strict regulations and tariffs as high as 17.5 percent on foreign formula. The Food and Drug Administration maintains a “red list” of international formulas, including several European brands that, if imported, are detained because they do not meet U.S. requirements. Those shortcomings could include labels that are not written in English or do not have all of the required nutrients listed. This week, the FDA said it would relax some regulations to allow for more imports into the United States.
Trade rules contained in the United States-mexico-canada Agreement, which replaced the North American Free Trade Agreement, also significantly discourage Canadian companies from exporting infant formula to the United States. The pact established low quotas that trigger export charges if exceeded. American dairy lobbying groups had urged officials to swiftly pass the agreement and supported the quotas at the time.
But perhaps the biggest barrier to new entrants is the structure of a program that aims to help low-income families obtain formula. The Special Supplemental Nutrition Program for Women, Infants, and Children, better known as WIC, is a federally funded program that provides grants to states to ensure that low-income pregnant or postpartum women and their children have access to food.
The program, which is administered by state agencies, purchases more than half of all infant formula supply in the United States, with about 1.2 million infants receiving formula through WIC.
State WIC agencies cannot just buy formula from any manufacturer. They are required by law to competitively bid for contracts and select one company, which becomes the exclusive provider of formula for all WIC recipients in the state. In exchange for those exclusive rights, manufacturers must provide states significant discounts for the formula they purchase.
David E. Davis, an economics professor at South Dakota State University, said that exclusive system could make it more difficult for smaller companies to break through. Although manufacturers may sell products to states below cost, Davis’ research found that brands that secure WIC contracts gain greater prominence on store shelves, creating a spillover effect and resulting in larger sales among families that are not WIC recipients. Doctors may also preferentially recommend those brands to mothers, his research found.
“If you don’t have the WIC contract, you’re pretty much a small player,” Davis said. “Because that locks you out of the WIC market and it pretty much locks you out of the non-wic market. So firms bid very aggressively to get the WIC contract.”
Only three companies have contracts to supply formula through the program: Abbott makes up the largest share, providing formula to about 47 percent of infants who receive WIC benefits, while Mead Johnson provides 40 percent and Gerber, which is manufactured by Nestlé, provides 12 percent, according to the National WIC Association.
In the early 1990s, the FTC filed a lawsuit against Abbott, accusing it and the other large manufacturers at the time, Mead Johnson and American Home Products, of price-fixing and bid-rigging in the process of bidding for state WIC contracts. Mead Johnson and American Home Products settled before the FTC brought its case against Abbott. Abbott won the case when a judge concluded that the company had not conspired or engaged in unfair competition in the auctions.
To help alleviate the shortage, the Agriculture Department has granted states waivers that would give WIC recipients more flexibility to choose alternative formula brands and sizes, although not every state has adopted all of the waivers.
While the bidding process could be limiting competition, the federal government saves about $1.7 billion each year with states negotiating for rebates. Tiare Sanna, director of Oregon’s WIC program, said that mothers in the state are now facing difficulty finding formula because the state contracts with Abbott, but the bidding system normally allows the state to serve a greater number of participants because it is able to buy more formula at the discounted rate.
“If we had to use our WIC food dollars to purchase formula at shelf price, we would have to significantly decrease the amount of participants that we serve,” Sanna said. “So this is a means of allowing us to serve the greatest amount of infants as possible, but I do acknowledge that it can create some issues.”
The Biden administration has announced a series of steps to address the shortages, including invoking the Defense Production Act to ramp up manufacturing and deploying Defense Department planes to speed shipments to the United States.
Still, officials acknowledged Thursday that the shortage was expected to persist into next month, in large part because the Abbott plant has yet to restart production.
Many Republicans, including Sen. Mitch Mcconnell, R-KY., the minority leader, have blamed President Joe Biden for the shortages, saying the administration should have moved more quickly to limit the fallout from the plant closing.